{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:18Z","timestamp":1792787898752,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University","award":["(IO) R016737004"],"award-info":[{"award-number":["(IO) R016737004"]}],"id":[{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University","award":["(IO) R016833011"],"award-info":[{"award-number":["(IO) R016833011"]}],"id":[{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Research Council of Thailand (NRCT) and Mahidol University","id":[{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05004-6","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:38:26Z","timestamp":1782484706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids"],"prefix":"10.1186","volume":"24","author":[{"given":"Nattaporn","family":"Phanthaphol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Kanoksing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woramin","family":"Riansuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriluck","family":"Prapasrivorakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornraksa","family":"Ovartchaiyapong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitsariya","family":"Mongkhonsupphawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surat","family":"Phumphuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peti","family":"Thuwajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanitra","family":"Thuwajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyanee","family":"Thongchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"5004_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3390\/biomedicines13071646","volume":"13","author":"AS Adebayo","year":"2025","unstructured":"Adebayo AS, Adeleke A, Adesina SK, Agbaje K, Olajubutu O. Colorectal cancer: therapeutic approaches and their complications. Biomedicines. 2025;13:1646.","journal-title":"Biomedicines"},{"key":"5004_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"5004_CR3","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-18-2022","volume":"79","author":"Y Yokoyama","year":"2019","unstructured":"Yokoyama Y, Lew ED, Seelige R, Tindall EA, Walsh C, Fagan PC, et al. Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor. Cancer Res. 2019;79:1996\u20132008.","journal-title":"Cancer Res"},{"key":"5004_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.5306\/wjco.v15.i9.1136","volume":"15","author":"H Fadlallah","year":"2024","unstructured":"Fadlallah H, El Masri J, Fakhereddine H, Youssef J, Chemaly C, Doughan S, et al. Colorectal cancer: recent advances in management and treatment. World J Clin Oncol. 2024;15:1136\u201356.","journal-title":"World J Clin Oncol"},{"key":"5004_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/EDBK_349811","volume":"42","author":"IH Sahin","year":"2022","unstructured":"Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R. Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ Book. 2022;42:242\u201353.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5004_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W. Immunotherapy in microsatellite-stable colorectal cancer: strategies to overcome resistance. Crit Rev Oncol Hematol. 2025;212:104775.","journal-title":"Crit Rev Oncol Hematol"},{"key":"5004_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s10238-024-01347-7","volume":"24","author":"P Rujirachaivej","year":"2024","unstructured":"Rujirachaivej P, Siriboonpiputtana T, Luangwattananun P, Yuti P, Wutti-In Y, Choomee K, et al. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma. Clin Exp Med. 2024;24:90.","journal-title":"Clin Exp Med"},{"key":"5004_CR8","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang C, Wang J, Che S, Zhao H. CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon. 2023;9:e21959.","journal-title":"Heliyon"},{"key":"5004_CR9","unstructured":"Arjumand S CAR-T cell therapy and its engineering marvels in cancer immunotherapy: a comprehensive review. BRAC University. 2024. Available from: https:\/\/dspace.bracu.ac.bd\/xmlui\/handle\/10361\/25697"},{"key":"5004_CR10","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5004_CR11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","volume":"9","author":"J Cheng","year":"2019","unstructured":"Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237.","journal-title":"Front Oncol"},{"key":"5004_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1652329","volume":"15","author":"J Guo","year":"2025","unstructured":"Guo J, Zhou C, Zhao H, Li H. Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors. Front Oncol. 2025;15:1652329.","journal-title":"Front Oncol"},{"key":"5004_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells14050320","volume":"14","author":"B Zhang","year":"2025","unstructured":"Zhang B, Wu J, Jiang H, Zhou M. Strategies to overcome antigen heterogeneity in CAR-T cell therapy. Cells. 2025;14:320.","journal-title":"Cells"},{"key":"5004_CR14","doi-asserted-by":"publisher","first-page":"11781","DOI":"10.3390\/ijms222111781","volume":"22","author":"C Aparicio","year":"2021","unstructured":"Aparicio C, Belver M, Enriquez L, Espeso F, Nunez L, Sanchez A, et al. Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells. Int J Mol Sci. 2021;22:11781.","journal-title":"Int J Mol Sci"},{"key":"5004_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.21037\/atm-22-6196","volume":"10","author":"X Yi","year":"2022","unstructured":"Yi X, Hu W. Advances in adoptive cellular therapy for colorectal cancer: a narrative review. Ann Transl Med. 2022;10:1404.","journal-title":"Ann Transl Med"},{"key":"5004_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20230047","volume":"2","author":"K Qian","year":"2024","unstructured":"Qian K, Li G, Zhang S, Fu W, Li T, Zhao J, et al. CAR\u2010T\u2010cell products in solid tumors: progress, challenges, and strategies. Interdiscip Med. 2024;2:e20230047.","journal-title":"Interdiscip Med"},{"key":"5004_CR17","doi-asserted-by":"publisher","first-page":"TPS2699","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2699","volume":"42","author":"SR Punekar","year":"2024","unstructured":"Punekar SR, Hecht JR, Smith CJ, Simeone DM, Dorigo O, Boyd LR, et al. EVEREST-2: A seamless phase 1\/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A* 02 loss of heterozygosity (LOH). J Clin Oncol. 2024;42:TPS2699.","journal-title":"J Clin Oncol"},{"key":"5004_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2741\/4877","volume":"25","author":"X Li","year":"2020","unstructured":"Li X, Berahovich R, Zhou H, Liu X, Li F, Xu S, et al. PLAP-CAR T cells mediate high specific cytotoxicity against colon cancer cells. Front Biosci (Landmark Ed). 2020;25:1765\u201386.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"5004_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433981","volume":"7","author":"M Dosset","year":"2018","unstructured":"Dosset M, Vargas TR, Lagrange A, Boidot R, V\u00e9gran F, Roussey A, et al. PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7:e1433981.","journal-title":"Oncoimmunology"},{"key":"5004_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/cancers15051357","volume":"15","author":"X Zhai","year":"2023","unstructured":"Zhai X, Mao L, Wu M, Liu J, Yu S. Challenges of anti-mesothelin CAR-T-cell therapy. Cancers (Basel). 2023;15:1357.","journal-title":"Cancers (Basel)"},{"key":"5004_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41577-019-0248-y","volume":"20","author":"YE Bar-Ephraim","year":"2020","unstructured":"Bar-Ephraim YE, Kretzschmar K, Clevers H. Organoids in immunological research. Nat Rev Immunol. 2020;20:279\u201393.","journal-title":"Nat Rev Immunol"},{"key":"5004_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1248","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu L, Li Z, Mei H, Li W, Chen D, Liu L, et al. Patient\u2010derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR\u2010T cells in vitro. Clin Transl Immunology. 2021;10:e1248.","journal-title":"Clin Transl Immunology"},{"key":"5004_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626369","volume":"16","author":"M Jassin","year":"2025","unstructured":"Jassin M, Block A, Desiront L, Vrancken L, Gregoire C, Baron F, et al. From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. Front Immunol. 2025;16:1626369.","journal-title":"Front Immunol"},{"key":"5004_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115691","volume":"168","author":"P Yuti","year":"2023","unstructured":"Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, et al. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother. 2023;168:115691.","journal-title":"Biomed Pharmacother"},{"key":"5004_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06453-y","volume":"23","author":"N Phanthaphol","year":"2025","unstructured":"Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, Yuti P, Sujjitjoon J, Augsornworawat P, et al. Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 and secreting anti-PD-L1 scFv. J Transl Med. 2025;23:451.","journal-title":"J Transl Med"},{"key":"5004_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03625-3","volume":"22","author":"S Thongchot","year":"2024","unstructured":"Thongchot S, Aksonnam K, Prasopsiri J, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, et al. Mesothelin-and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells. BMC Med. 2024;22:400.","journal-title":"BMC Med"},{"key":"5004_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5462-2","volume":"19","author":"TP Sandberg","year":"2019","unstructured":"Sandberg TP, Stuart MP, Oosting J, Tollenaar RA, Sier CF, Mesker WE. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer. 2019;19:284.","journal-title":"BMC Cancer"},{"key":"5004_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s10637-025-01523-w","volume":"43","author":"N Yao","year":"2025","unstructured":"Yao N, Jing N, Lin J, Nui W, Yan W, Yuan H, et al. Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application. Invest New Drugs. 2025;43:394\u2013404.","journal-title":"Invest New Drugs"},{"key":"5004_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109442","volume":"113","author":"P Yuti","year":"2022","unstructured":"Yuti P, Wutti-In Y, Sawasdee N, Kongkhla K, Phanthaphol N, Choomee K, et al. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. Int Immunopharmacol. 2022;113:109442.","journal-title":"Int Immunopharmacol"},{"key":"5004_CR30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","volume":"11","author":"NA Johdi","year":"2020","unstructured":"Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies. Front Immunol. 2020;11:1624.","journal-title":"Front Immunol"},{"key":"5004_CR31","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3390\/jcm12052072","volume":"12","author":"O Hernandez Dominguez","year":"2023","unstructured":"Hernandez Dominguez O, Yilmaz S, Steele SR. Stage IV colorectal cancer management and treatment. J Clin Med. 2023;12:2072.","journal-title":"J Clin Med"},{"key":"5004_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB III, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41:678\u2013700.","journal-title":"J Clin Oncol"},{"key":"5004_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/bjs5.50299","volume":"4","author":"V V\u00e4yrynen","year":"2020","unstructured":"V\u00e4yrynen V, Wirta E, Sepp\u00e4l\u00e4 T, Sihvo E, Mecklin J, Vasala K, et al. Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study. BJS Open. 2020;4:685\u201392.","journal-title":"BJS Open"},{"key":"5004_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669\u201385.","journal-title":"JAMA"},{"key":"5004_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221136440","volume":"29","author":"VS Pankratz","year":"2022","unstructured":"Pankratz VS, Kanda D, Edwardson N, English K, Adsul P, Li Y, et al. Colorectal cancer survival trends in the United States from 1992 to 2018 differ among persons from five racial and ethnic groups according to stage at diagnosis: a SEER-based study. Cancer Control. 2022;29:10732748221136440.","journal-title":"Cancer Control"},{"key":"5004_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/nov157","volume":"18","author":"DJ Silver","year":"2015","unstructured":"Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD. The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol. 2015;18:153\u20139.","journal-title":"Neuro Oncol"},{"key":"5004_CR37","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.4251\/wjgo.v17.i7.106723","volume":"17","author":"M-Y Chen","year":"2025","unstructured":"Chen M-Y, Wang C, Wang Y-G, Shi M. Adoptive cell therapy in colorectal cancer: advances in chimeric antigen receptor T cells. World J Gastrointest Oncol. 2025;17:106723.","journal-title":"World J Gastrointest Oncol"},{"key":"5004_CR38","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelg\u00e5rd G, Wenthe J, L\u00f6vgren T, Amini RM, et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24:6185\u201394.","journal-title":"Clin Cancer Res"},{"key":"5004_CR39","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2024024381","volume":"144","author":"K Maurer","year":"2024","unstructured":"Maurer K, Grabski IN, Houot R, Gohil SH, Miura S, Redd R, et al. Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood. 2024;144:2490\u2013502.","journal-title":"Blood"},{"key":"5004_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114621","volume":"43","author":"MR Ulibarri","year":"2024","unstructured":"Ulibarri MR, Lin Y, Ramprashad JC, Han G, Hasan MH, Mithila FJ, et al. Epithelial organoid supports resident memory CD8 T cell differentiation. Cell Rep. 2024;43:114621.","journal-title":"Cell Rep"},{"key":"5004_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers HJS. Cancer modeling meets human organoid technology. Science. 2019;364:952\u20135.","journal-title":"Science"},{"key":"5004_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11:eaay2574.","journal-title":"Sci Transl Med"},{"key":"5004_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152884","volume":"216","author":"M Zhang","year":"2020","unstructured":"Zhang M, Shi R, Guo Z, He J. Cancer-associated fibroblasts promote cell growth by activating ERK5\/PD-L1 signaling axis in colorectal cancer. Pathol Res Pract. 2020;216:152884.","journal-title":"Pathol Res Pract"},{"key":"5004_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/1878-0261.13727","volume":"19","author":"H Niedra","year":"2025","unstructured":"Niedra H, Peculis R, Saksis R, Mandrika I, Vilisova S, Nazarovs J, et al. Tumor and \u03b1\u2010SMA\u2010expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade. Mol Oncol. 2025;19:659\u201381.","journal-title":"Mol Oncol"},{"key":"5004_CR45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00432-022-04493-1","volume":"149","author":"N Jiang","year":"2023","unstructured":"Jiang N, Yu Y, Wu D, Wang S, Fang Y, Miao H, et al. HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. J Cancer Res Clin Oncol. 2023;149:737\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5004_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978195","volume":"13","author":"B Ghazi","year":"2022","unstructured":"Ghazi B, El Ghanmi A, Kandoussi S, Ghouzlani A, Badou A. CAR T-cells for colorectal cancer immunotherapy: ready to go? Front Immunol. 2022;13:978195.","journal-title":"Front Immunol"},{"key":"5004_CR47","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537\u201344.","journal-title":"Blood"},{"key":"5004_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.copbio.2020.05.002","volume":"65","author":"K Homicsko","year":"2020","unstructured":"Homicsko K. Organoid technology and applications in cancer immunotherapy and precision medicine. Curr Opin Biotechnol. 2020;65:242\u20137.","journal-title":"Curr Opin Biotechnol"},{"key":"5004_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ymthe.2024.11.017","volume":"33","author":"S Navarro","year":"2025","unstructured":"Navarro S, Moukheiber C, Sancho SI, Guill\u00e9n MR, Cerio ALD, Sanges C, et al. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. Mol Ther. 2025;33:847\u201365.","journal-title":"Mol Ther"},{"key":"5004_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.seminhematol.2020.07.005","volume":"57","author":"OL Reddy","year":"2020","unstructured":"Reddy OL, Stroncek DF, Panch SR. Improving CAR T cell therapy by optimizing critical quality attributes. Semin Hematol. 2020;57:33\u20138.","journal-title":"Semin Hematol"},{"key":"5004_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add5976","volume":"8","author":"NV Gavil","year":"2023","unstructured":"Gavil NV, Sade-Feldman M, Yizhak K, Tabach Y, Tirosh I, Suv\u00e0 ML, et al. Chronic antigen in solid tumors drives a distinct program of T cell residence. Sci Immunol. 2023;8:eadd5976.","journal-title":"Sci Immunol"},{"key":"5004_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Li X, Zhang C, Liu Z, Wang Z, Chen J, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"5004_CR53","doi-asserted-by":"publisher","first-page":"e006454","DOI":"10.1136\/jitc-2022-006454","volume":"11","author":"J Jung","year":"2023","unstructured":"Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer. 2023;11:e006454.","journal-title":"J Immunother Cancer"},{"key":"5004_CR54","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ. Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735\u201347.","journal-title":"Nat Rev Immunol"},{"key":"5004_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.gpb.2019.03.002","volume":"17","author":"I Xhangolli","year":"2019","unstructured":"Xhangolli I, Dura B, Lee G, Kim D, Xiao Y, Fan R. Single-cell analysis of CAR-T cell activation reveals a mixed Th 1\/Th 2 response independent of differentiation. Genom. Proteom. Bioinform. 2019;17:129\u201339.","journal-title":"Genom. Proteom. Bioinform."},{"key":"5004_CR56","first-page":"39","volume":"3","author":"NJ Llosa","year":"2014","unstructured":"Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. Interleukin-17 and type 17 helper T cells in cancer management and research. Immunotargets Ther. 2014;3:39\u201354.","journal-title":"Immunotargets Ther"},{"key":"5004_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807915","volume":"13","author":"L Wen","year":"2022","unstructured":"Wen L, Li J, Guo H, Liu X, Zheng S, Zhang Y, et al. Single-cell RNA-seq reveals the potential risk of anti-mesothelin CAR T cell therapy toxicity to different organs in humans. Front Immunol. 2022;13:807915.","journal-title":"Front Immunol"},{"key":"5004_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118806","volume":"193","author":"C Somboonpatarakun","year":"2025","unstructured":"Somboonpatarakun C, Thuwajit P, Thuwajit C, Sricharunrat T, Sungsri T, Srisawat T, et al. Next-generation CAR T cells targeting integrin \u03b1v\u03b26 and PD-L1 to enhance immunotherapy for cholangiocarcinoma. Biomed Pharmacother. 2025;193:118806.","journal-title":"Biomed Pharmacother"},{"key":"5004_CR59","doi-asserted-by":"publisher","first-page":"101503","DOI":"10.1016\/j.xpro.2022.101557","volume":"3","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Doi H, Koyama S, Yoshida M, Takahashi H, Tanaka Y, et al. Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protoc. 2022;3:101503.","journal-title":"STAR Protoc"},{"key":"5004_CR60","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175:1972\u20131988.e16.","journal-title":"Cell"},{"key":"5004_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00262-024-03749-8","volume":"73","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang Y, Wang X, Chen L, Liu H, Zhao Y, et al. Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures. Cancer Immunol Immunother. 2024;73:164.","journal-title":"Cancer Immunol Immunother"},{"key":"5004_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2025.2567802","volume":"26","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang X, Zhang J, Li H, Chen Z, Zhou Y, et al. Patient-derived organoids (PDOs) as a promising platform for personalized treatment of colorectal cancer: current applications and future challenges. Cancer Biol Ther. 2025;26:2567802.","journal-title":"Cancer Biol Ther"},{"key":"5004_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Zhang Y, Liu X, Wang J, Chen H, Li Z, et al. Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:29.","journal-title":"Mol Cancer"},{"key":"5004_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.748465","volume":"11","author":"Y Gao","year":"2021","unstructured":"Gao Y, Sun Z, Gu J, Li Z, Xu X, Xue C, et al. Cancer-associated fibroblasts promote the upregulation of PD-L1 expression through Akt phosphorylation in colorectal cancer. Front Oncol. 2021;11:748465.","journal-title":"Front Oncol"},{"key":"5004_CR65","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320\u201332.","journal-title":"Gut"},{"key":"5004_CR66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"CM Ayala","year":"2024","unstructured":"Ayala CM, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.","journal-title":"J Exp Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05004-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05004-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05004-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:02:16Z","timestamp":1789524136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05004-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5004"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05004-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The written informed consent from healthy volunteers under the Ethics approval protocol by the Siriraj Institutional Review Board, Faculty of Medicine Siriraj Hospital, Mahidol University (COA no. Si 617\/2024).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"493"}}